| Title | Gentamicin reduces serum ACE activity in patients with normal kidney function. | | Author(s) | Ziai SA, Mooraki A, Mahmoudian M | | Institution | Department of Pharmacology, Institute of Medicinal Plants and Natural Products, ACECR, Tehran, Iran. | | Source | Am J Nephrol 2002 Sep-Dec; 22(5-6):487-90. | | MeSH | Acetylglucosaminidase
Adult
Biological Markers
Comparative Study
Creatinine
Fractures, Bone
Gentamicins
Humans
Kidney
Peptidyl-Dipeptidase A
Research Support, Non-U.S. Gov't
| | Abstract | AIMS: We evaluated serum angiotensin-converting enzyme (ACE) as an indicator of gentamicin toxicity and compared it with N-acetyl-beta-D-glucosaminidase (NAG) and creatinine.
METHODS: 20 bone fracture in-patients receiving gentamicin 80 mg TDS for 3 days. Subjects had normal kidney function and had no history or sign of hypertension. Serum and urine samples were collected before and 3 days after drug administration. Samples analyzed for ACE, NAG, BUN, creatinine, sodium, and potassium.
RESULTS: Our results showed that urine NAG activity increased significantly at the 3rd day. Serum creatinine level and glomerular filtration rate (GFR) while still at a normal range showed slight but significant changes at this time. This may indicate some renal damage. Serum ACE activity decreased significantly at the 3rd day.
CONCLUSION: These results indicate serum ACE can be used as a good indicator of renal damage in patients receiving gentamicin. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 12381948 |
|
